ScreenerHero
CDNACareDx, Inc.
NAS · US · Healthcare · Diagnostics & Research · caredx.com
46.40USD-0.24%Mkt Cap: 2.41B $P/E: 22.36

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1

Key Statistics

Company
Market Cap2.41B $
Enterprise Value2.08B $
Revenue (TTM)458.09M $
Gross Profit256.57M $
Net Income (TTM)-21.35M $
Revenue/Share8.886 USD
Last Price46.40 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees761
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS14167L1035
Valuation
P/E (Trailing)22.36
P/E (Forward)34.68
PEG—
EV/EBITDA167.02
EV/Revenue4.53
P/S5.31
P/B5.68
EPS (TTM)2.10
EPS (Forward)1.35
52W Range
11.2791% of range49.76
52W High49.76 USD
52W Low11.27 USD
Profitability
Gross Margin67.55%
Oper. Margin0.19%
EBITDA Margin2.71%
Profit Margin-5.62%
ROE-7.05%
ROA-5.17%
Growth
Revenue Growth52.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF42.03M $
CapEx (TTM)6.59M $
FCF Margin24.48%
FCF Yield4.66%
Net Debt-354.39M $
Net Debt/EBITDA-28.50
Balance Sheet
Debt/Equity0.09
Current Ratio4.58
Quick Ratio4.36
Book Value/Sh8.267 USD
Cash/Share7.222 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.33 USD
Upside (mean)+12.8%
Target Range40.00 USD – 64.00 USD
$40.00+12.8% to mean$64.00
# Analysts6
Ownership
Shares Out.51.73M
Float49.47M
Insiders3.16%
Institutions103.41%
Short Interest
Short Ratio5.4d
Short % Float12.08%
Short % Out.11.86%
Shares Short6.14M
Short (prev mo.)8.34M
Technical
SMA 5035.17 (+31.9%)
SMA 20023.18 (+100.1%)
Beta2.42
S&P 52W Chg18.16%
Avg Vol (30d)1.17M
Avg Vol (10d)963.62K
Technical Indicators
RSI (14)67.9
MACD3.7985
MACD Signal4.1205
MACD Hist.-0.3220
BB Upper52.61 USD
BB Middle43.05 USD
BB Lower33.49 USD
BB Width44.41%
ATR (14)2.122 USD
Vol Ratio (20d)1.71x